Journal
JOURNAL OF CLINICAL VIROLOGY
Volume 148, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jcv.2022.105120
Keywords
COVID-19; Biomarker; Immunity
Categories
Ask authors/readers for more resources
This study investigated the TTV DNA load, SARS-CoV-2 RNAemia, and IgM/IgG antibodies in COVID-19 positive patients, and found that TTV DNA load and SARS-CoV-2 RNAemia could serve as non-invasive markers reflecting disease severity and poor outcome.
Rationale/Objectives: SARS-CoV-2 is the cause of worldwide COVID-19, which severity has been linked to the immune and inflammatory response. Here, we investigate Torquetenovirus (TTV) DNA load a marker reflecting the intensity of the overall immune response as well as SARS-CoV-2 RNAemia and IgM/IgG antibodies in COVID-19-positive patients.Methods: Two hundred and fifteen COVID-19-positive patients were enrolled, including 87 severe cases and 128 mild-moderate cases. SARS-CoV-2 RNAemia and IgM/IgG antibodies, as well as TTV DNA loads, were measured on longitudinal plasma samples.Results: The rate of severe cases was higher in patients with low TTV DNA load in plasma considering a threshold of 700 copies/mL. In severe patients, SARS-CoV-2 RNAemia positivity rates were higher than those in mild moderate cases at any timepoint. When combined, TTV DNA load and SARS-CoV-2 RNAemia allowed to predict the outcome of COVID-19 infection, with a higher risk (HR=12.4) of ICU admission in patients with low TTV DNA load and positive SARS-CoV-2 RNAemia.Conclusions: TTV DNA load and SARS-CoV-2 RNAemia may be effective, non-invasive markers reflecting disease severity and poor outcome that could be conveniently measured in a clinical laboratory setting, as soon as COVID-19 diagnosis is made.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available